Innoviva files risk factor update with no specific new disclosure

Innoviva, Inc.

Filed an 8-K to supplement risk factors from its June 30, 2022 10-Q and 2021 10-K.
Updated risk factors cover clinical trial failure, patient enrollment delays, and third-party dependence.
No specific new events, financial results, or business developments were reported.
The risk factor language is standard biotech boilerplate with no material changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.